Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients.
Peng Luo, Yanxi Ding, Weiye Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the prognostic effects of seven antidiabetic medication classes in over 1.1 million cancer patients, primarily with type 2 diabetes. It found that metformin was associated with lower all-cause mortality (HR=0.82) and cancer-specific mortality (HR=0.77), while insulin was linked to higher all-cause mortality (HR=2.03).
Key findings
- Metformin use was associated with lower all-cause mortality (HR=0.82, 95% CI: 0.74-0.91).
- Insulin use was associated with higher all-cause mortality (HR=2.03, 95% CI: 1.63-2.51).
- SGLT2 inhibitors showed a nonsignificant inverse trend with all-cause mortality (HR=0.44, 95% CI: 0.11-1.71).
- Metformin and insulin associations were consistent in adjusted analyses, while other comparisons were less reliable.
Why it matters
Understanding the differential impacts of antidiabetic medications on cancer prognosis is crucial for optimizing treatment strategies in patients with concurrent diabetes and cancer, potentially influencing survival outcomes.
What to keep in mind
The evidence primarily stems from observational studies with substantial heterogeneity and limited data on newer agents.